Update on the cefdinir spectrum and potency against pathogens isolated from uncomplicated skin and soft tissue infections in North America: are we evaluating the orally administered cephalosporins correctly?

Diagnostic Microbiology and Infectious Disease

Volumn 55, Issue 4, 2006, Pages 351-356

  Jones, Ronald N ^a,b   Sader, Helio S ^a,c  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

CA MRSA; Cefdinir; Cephalexin; Cephalosporins; Reevaluation; Resistance; uSSTI

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; CEFALEXIN; CEFALOTIN; CEFAZOLIN; CEFDINIR; CEFPROZIL; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; DOXYCYCLINE; ERYTHROMYCIN; LINEZOLID; OXACILLIN; PENICILLIN G;

ARTICLE; DISEASE PREDISPOSITION; DRUG POTENCY; ESCHERICHIA COLI; EVALUATION; HUMAN; KLEBSIELLA PNEUMONIAE; NONHUMAN; NORTH AMERICA; PRIORITY JOURNAL; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS;

ADMINISTRATION, ORAL; ANTI-INFECTIVE AGENTS; CEPHALOSPORINS; DRUG RESISTANCE, BACTERIAL; GRAM-POSITIVE COCCI; HUMANS; MICROBIAL SENSITIVITY TESTS; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS;

EID: 33746436622     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2006.04.015     Document Type: Article

References (18)

1. Clinical and Laboratory Standards Institute. Approved Standards M7-A7: methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 7th ed. (2006), CLSI, Wayne (PA)
2. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing, 16th informational supplement M100-S16 (2006), CLSI, Wayne (PA)
3. Cohen M.A., Joannides E.T., Roland G.E., Meservey M.A., Huband M.D., Shapiro M.A., Sesnie J.C., and Heifetz C.L. In vitro evaluation of cefdinir (FK482), a new oral cephalosporin with enhanced antistaphylococcal activity and beta-lactamase stability. Diagn. Microbiol. Infect. Dis. 18 (1994) 31-39
4. Deresinski S. Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey. Clin. Infect. Dis. 40 (2005) 562-573
5. Fung H.B., Chang J.Y., and Kuczynski S. A practical guide to the treatment of complicated skin and soft tissue infections. Drugs 63 (2003) 1459-1480
6. Guay D.R. Pharmacodynamics and pharmacokinetics of cefdinir, an oral extended spectrum cephalosporin. Pediatr. Infect. Dis J. 19 (2000) S141-S146
7. Klein J.O., and McCracken Jr. G.H. Summary: role of a new oral cephalosporin, cefdinir, for therapy of infections of infants and children. Pediatr. Infect. Dis J. 19 (2000) S181-S183
8. Low D.E. The new oral cephalosporins in community-acquired infections. Clin. Microbiol. Infect. 6 Suppl. 3 (2000) 64-69
9. Mine Y., Kamimura T., Watanabe Y., Tawara S., Matsumoto Y., Shibayama F., Kikuchi H., Takaya T., and Kuwahara S. In vitro antibacterial activity of FK482, a new orally active cephalosporin. J. Antibiot. (Tokyo) 41 (1988) 1873-1887
10. Package Insert. Omnicef (cefdinir) (2004), Abbott Laboratories, North Chicago (IL). http://www.rxabbott.com/pdf/omnicef.PDF Available at http://www.rxabbott.com/pdf/omnicef.PDF. [Accessed May 2006]
11. Powers J.L., Gooch III W.M., and Oddo L.P. Comparison of the palatability of the oral suspension of cefdinir vs. amoxicillin/clavulanate potassium, cefprozil and azithromycin in pediatric patients. Pediatr. Infect. Dis J. 19 (2000) S174-S180
12. Sader H.S., Fritsche T.R., Mutnick A.H., and Jones R.N. Contemporary evaluation of the in vitro activity and spectrum of cefdinir compared with other orally administered antimicrobials tested against common respiratory tract pathogens (2000-2002). Diagn. Microbiol. Infect. Dis. 47 (2003) 515-525
13. Sader H.S., Streit J.M., Fritsche T.R., and Jones R.N. Potency and spectrum reevaluation of cefdinir tested against pathogens causing skin and soft tissue infections: a sample of North American isolates. Diagn. Microbiol. Infect. Dis. 49 (2004) 283-287
14. Steele R.W., Thomas M.P., and Begue R.E. Compliance issues related to the selection of antibiotic suspensions for children. Pediatr. Infect. Dis J. 20 (2001) 1-5
15. Stevens D.L., Bisno A.L., Chambers H.F., Everett E.D., Dellinger P., Goldstein E.J., Gorbach S.L., Hirschmann J.V., Kaplan E.L., Montoya J.G., and Wade J.C. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin. Infect. Dis. 41 (2005) 1373-1406
16. Tack K.J., Keyserling C.H., McCarty J., and Hedrick J.A. Study of use of cefdinir versus cephalexin for treatment of skin infections in pediatric patients. The Cefdinir Pediatric Skin Infection Study Group. Antimicrob. Agents Chemother. 41 (1997) 739-742
17. Tack K.J., Littlejohn T.W., Mailloux G., Wolf M.M., and Keyserling C.H. Cefdinir versus cephalexin for the treatment of skin and skin-structure infections. The Cefdinir Adult Skin Infection Study Group. Clin. Ther. 20 (1998) 244-256
18. Tenover F.C., McDougal L.K., Goering R.V., Killgore G., Projan S.J., Patel J.B., and Dunman P.M. Characterization of a strain of community-associated methicillin-resistant Staphylococcus aureus widely disseminated in the United States. J. Clin. Microbiol. 44 (2006) 108-118